Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human

References

• Akabane T, Tabata K, Kadono K, et al (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308–16
   PubMed Web of Science ®Google Scholar
• Baer BR, Wienkers LC, Rock DA. (2007). Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954–64
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Bertrand M, Jackson P, et al (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–52
   PubMed Web of Science ®Google Scholar
• Chen B, Dong JQ, Pan WJ, Ruiz A. (2012). Pharmacokinetics/pharmacodynamics model-supported early drug development. Curr Pharm Biotechnol 13:1360–75
   PubMed Web of Science ®Google Scholar
• Chu X, Shih SJ, Shaw R, et al (2015). Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans. Drug Metab Dispos 43:851–63
   PubMed Web of Science ®Google Scholar
• Domanski TL, Halpert JR. (2001). Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117–37
   PubMed Web of Science ®Google Scholar
• Dresser GK, Spence JD, Gailey DG. (2000). Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57
   PubMed Web of Science ®Google Scholar
• Ernest CS, Hall SD, Jones DR. (2005). Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583–91
   PubMed Web of Science ®Google Scholar
• Foti RS, Rock DA, Pearson JT, et al (2011). Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction. Drug Metab Dispos 39:1188–95
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355–70
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17
   PubMed Web of Science ®Google Scholar
• Hajjar ER, Cafiero AC, Hanlon JT. (2007). Polypharmacy in elderly patients. Am J Geriatr Pharmacother 5:345–51
   PubMedGoogle Scholar
• Iwasaki K, Murayama N, Koizumi R, et al (2010). Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab Pharmacokinet 25:388–91
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Uno Y. (2009). Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica 39:578–81
   PubMed Web of Science ®Google Scholar
• Jones DR, Gorski JC, Hamman MA, et al (1999). Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116–25
   PubMed Web of Science ®Google Scholar
• Kanazu T, Yamaguchi Y, Okamura N, et al (2004). Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391–402
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Domanski TL, Halpert JR. (2002). Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495–506
   PubMed Web of Science ®Google Scholar
• Koyanagi T, Nakanishi Y, Murayama N, et al (2014). Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro–in vivo correlation. Xenobiotica 45:312–21
   PubMed Web of Science ®Google Scholar
• Kronbach T, Mathys D, Umeno M, et al (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89–96
   PubMed Web of Science ®Google Scholar
• Lasser KE, Allen PD, Woolhandler SJ, et al (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–20
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling AL, Quigley SD, et al (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162–72
   PubMed Web of Science ®Google Scholar
• Lin HL, Kent UM, Hollenberg PF. (2005). The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154–64
   PubMed Web of Science ®Google Scholar
• Lin HL, Kenaan C, Hollenberg PF. (2012). Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab Dispos 40:998–1006
   PubMed Web of Science ®Google Scholar
• Ma B, Prueksaritanont T, Lin JH. (2000). Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28:125–30
   PubMed Web of Science ®Google Scholar
• McConn DJ, 2nd, Lin YS, Allen K, et al (2004). Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083–91
   PubMed Web of Science ®Google Scholar
• Nakamura K, Ariyoshi N, Iwatsubo T, et al (2005). Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull 28:882–5
   PubMed Web of Science ®Google Scholar
• Ogawa K, Kato M, Houjo T, Ishigai M. (2013). A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. Xenobiotica 43:468–78
   PubMed Web of Science ®Google Scholar
• Ogasawara A, Kume T, Kazama E. (2007). Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410–18
   PubMed Web of Science ®Google Scholar
• Ogasawara A, Negishi I, Kozakai K, Kume T. (2009). In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys. Drug Metab Dispos 37:2127–36
   PubMed Web of Science ®Google Scholar
• Pearson JT, Wahlstrom JL, Dickmann LJ, et al (2007). Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 20:1778–86
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Lin JH. (2001). Screening of drug candidates for their drug-drug interaction potential. Curr Opin Chem Biol 5:396–401
   PubMed Web of Science ®Google Scholar
• Selvakumar S, Bhutani P, Ghosh K, et al (2014). Expression and characterization of cynomolgus monkey cytochrome CYP3A4 in a novel human embryonic kidney cell–based mammalian systems. Drug Metab Dispos 42:369–76
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF, Poulos TL. (2013). Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans 42:3116–26
   PubMed Web of Science ®Google Scholar
• Sharer JE, Shipley LA, Vandenbranden MR, et al (1995). Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231–41
   PubMed Web of Science ®Google Scholar
• Shimada T, Mimura M, Inoue K, et al (1997). Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401–8
   PubMed Web of Science ®Google Scholar
• Takahashi M, Washio T, Suzuki N, et al (2009). The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343–53
   PubMed Web of Science ®Google Scholar
• Tang C, Prueksaritanont T. (2010). Use of in vivo animal models to assess pharmacokinetic drug-drug interactions. Pharm Res 27:1772–87
   PubMed Web of Science ®Google Scholar
• Uehara S, Murayama N, Nakanishi Y, et al (2011). Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654–61
   PubMed Web of Science ®Google Scholar
• Uehara S, Murayama N, Nakanishi Y, et al (2014). Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica 44:769–74
   PubMed Web of Science ®Google Scholar
• Uno Y, Hosaka S, Matsuno K, et al (2007). Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 466:98–105
   PubMed Web of Science ®Google Scholar
• Uno Y, Iwasaki K, Yamazaki H, Nelson DR. (2011). Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 43:346–61
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). (2012). Guidance for industry, drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations
   Google Scholar
• U.S. Food and Drug Administration (FDA). (2006). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm
   Google Scholar
• VandenBrink BM, Davis JA, Pearson JT, et al (2012). Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation. Mol Pharmacol 82:835–42
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–60
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–33
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VE, et al (2002). Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883–91
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–19
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Wong YN. (2005). Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 6:241–57
   PubMed Web of Science ®Google Scholar